

INDOXYL SULFATE RELATED TO PROTEIN INTAKE AND INTRAHEMODYALYSIS ARTERIAL PRESSURE VARIATION, AND β_2 -MICROGLOBULIN TO ALBUMIN LEVELS AND INFLAMMATION

Juan Robles¹, Sheila Cabello², Loreto Quesada¹, Joana Ferrer³, Sergio Ibáñez², Juan Rey², Miguel Uriol², Bernardino Barceló¹, Joan Gascó²
¹Biochemistry, ²Nephrology, ³Immunology, Hospital Universitari Son Espases, Palma, Majorca, Balearic Islands, Spain

INTRODUCTION AND AIM

- Hypoalbuminemia is a strong factor for morbidity and mortality in the general and renal population. Inflammation and dietary protein intake exert competing effects on serum albumin over time.
- The nPCR is considered a valid surrogate for dietary protein intake under steady-state conditions, in the face of inflammation may overestimate protein intake because of endogenous nitrogen breakdown.
- High protein intake is associated with increased levels of albumin-bound uremic solutes in hemodialysis patients and this products show concentrations not determined by hemodialysis clearances.
- The objective of the study is to analyze the patterns of relationship of the prototypic uremic toxins with protein metabolism, inflammation, and other candidate clinical variables

METHODS 1: SAMPLES AND STATISTICS

- Cross-sectional study of 60 chronic hemodialysis (HD) patients.
- Pre/postHD total serum Indoxyl Sulfate (IS) by high-performance liquid chromatography (HPLC).
- Pre/post (post in hemodiafiltration patients-HDF-) serum β_2 -microglobulin (β_2M) by nephelometry.
- Urea kinetic model calculated by *Solute Solver* in midweek sessions: KD urea (urea dialyzer clearance), K dif urea (urea diffusive dialyzer clearance), Eq Kt/V (equilibrated Kt/V), KoA urea (urea mass transfer-area coefficient), G2p urea (urea double pool generation rate), TAC urea, SAN_DstdKt/V (weekly Dialysis Standard Kt/V normalized to body Surface Area), dp nPCR (normalized Protein Catabolic Rate double pool), V2p urea double pool.
- Testing of variables by Kolmogorov-Smirnov for normality ($p > 0,20$).
- T-test or ANOVA for IS and β_2M as dependent variables; and as categorical factors: albumin \geq or $<$ 38 g/L, dp nPCR categorized by levels, and albumin and dp nPCR profiles. T-test for albumin, dp nPCR and CRP as dependent variables; and as categorical factors: IS higher or lower than mean, and β_2M higher or lower than mean.
- Bivariate correlations (Pearson) and multiple regression analyses of IS and β_2M as dependent variables; as independent variables: biologic (hemoglobin, lymphocytes, BUN, urate, HCO₃⁻, P, Na, Log CRP, albumin by Bromocresol Green...), kinetic (SAN_DstdKt/V, dp nPCR, URR, IS reduction rate -RR-, β_2M RR...), and other clinical variables (residual diuresis, mean arterial pressure/MAP change, convective volume/CV in HDF, BMI, BSA...).
- MAP change: calculated as the difference between measures at the start and the end of each session. MAP = DAP+1/3(SAP-DAP).

METHODS 2: PATIENTS AND SESSIONS

- 60 patients of a university regional hospital based chronic haemodialysis unit.
- 60±20 (X±SD) years (range 20-84), 32 male (53,3%) / 28 (46,6%) female.
- Height 161,1±1,03 cm. Dry weight 67,5±19,3. BMI 25,5±0,9 kg/m². BSA 1,7±0,03 m².
- Modified Charlson's Index 7,2±2,85.
- Residual diuresis: 34 p null, 21 p <500 ml/24h, 5 p >500 ml/24 h.
- 21,66% (13 p) of the patients with positivity for hepatitis C/B or HIV: C hepatitis 8, B hepatitis 2, HIV 1, HIV and C hepatitis 1, B and C hepatitis 1.
- Haemodialysis session time 244±19'. Q_d 356,8±6,13 ml/min - Q_d standard HD 500-800 ml/min. Q_d HDF 800 ml/min.
- Dialyzers: Membrane: 56 polyneprhon, 4 cellulose. 34 High flux, 26 medium flux. Surface: 11 1.7 m², 33 1.9 m², 16 2.1 m².
- 29 p (48,3%) on line hemodiafiltration / 31 p (51,6%) standard hemodialysis.
- Ultrafiltration 2,3±0,93 L. Convective volume in HDF 23,8±2,8 L. Infusion volume in HDF 21,4±2,7 L.
- Mean dialysis prevalence months 46,8 (3,9 years) (range 3-299 months): mean 58,3 months HDF patients and 36 months standard HD patients.

METHODS 3: NORMALITY

Normality:
Indoxyl sulfate D=0,09 p>0,20, IS RR D=0,08 p>0,20, β_2 microglobulin (HDF) D=0,16 p>0,20, β_2 microglobulin (standard HD) D=0,14 p>0,20, β_2 microglobulin RR D=0,18 p>0,20, urea D=0,07 p>0,20, hemoglobin D=0,05 p>0,20, hematocrit D=0,06 p>0,20, leucocytes D=0,10 p>0,20, lymphocytes D=0,10 p>0,20, residual diuresis D=0,14 p>0,20, convective volume D=0,13 p>0,20, infusion volume D=0,16 p>0,20, HCO₃ D=0,09 p>0,20, pH D=0,09 p>0,20, P D=0,11 p>0,20, Log CRP D=0,05 p>0,20, MAP change D=0,07 p>0,20, urate D=0,12 p>0,20, height D=0,05 p>0,20, charlson index D=0,11 p>0,20, albumin D=0,10 p>0,20, dp nPCR D=0,08 p>0,20, Eq Kt/V urea D=0,06 p>0,20, G2p urea D=0,09 p>0,20, TAC urea D=0,07 p>0,20, BSA D=0,09 p>0,20

No normality:
URR D=0,14 p<0,15, prevalence months D=0,21 p<0,1, time in minutes D=0,35 p<0,01, Q_d D=0,28 p<0,1, PTH D=0,16 p<0,10, ionic Ca D=0,16 p<0,10, Na D=0,26 p<0,01, CRP D=0,32 p<0,01, BMI D=0,18 p<0,05, KoA urea D=0,25 p<0,01, KD urea D=0,17 p<0,10, K dif urea D=0,15 p<0,15, Ke D=0,19 p<0,05, V2p urea D=0,19 p<0,05, SAN_DstdKt/V D=0,19 p<0,05

METHODS 4: VARIABLES

Regression analysis:

- Indoxyl sulfate
- β_2 microglobulin
- Indoxyl sulfate reduction rate
- β_2 microglobulin reduction rate
- BUN preHD 78,6±1,8 mg/dl
- Hemoglobin 11,2±0,2 g/dl
- Hematocrit 34,4±0,5 %
- Lymphocytes 1.49±0,86,9 cel/mcl
- Albumin 37,8±0,5 g/L
- HCO₃ 23,9±0,3 mmol/L
- pH 7,4±0,01
- P 4,3±0,18 mg/dl
- Log CRP
- Urate 5,8±0,18 mg/dl
- Eq Kt/V 1,67±0,05
- G2p urea 5,3±0,26 mg/min
- TAC urea 34,3±1,26 mg/dl
- SAN_DstdKt/V: 2,7±0,07
- dp nPCR: 1,0±0,04 g/Kg/day
- Mean arterial pressure:
- Initial: 87,3±1,13 mmHg
- Final: 86,5±2,01 mmHg
- Mean arterial pressure change: -0,6 mmHg
- Modified Charlson index 7,2±2,85 points
- Height 161,1±1,03 cm
- Body surface area (BSA) 1,7±0,03 m².


METHODS 5: VARIABLES

Student-t /ANOVA:


- Dependent variables:**
- Indoxyl sulfate
 - β_2 microglobulin
- Categorical factors:**
- CRP \geq 1 mg/dl / $<$ 1 mg/dl
 - Albumin \geq 38 g/L / $<$ 38 g/L
 - dp nPCR \geq 1 / $<$ 1 g/Kg/day
 - dp nPCR (g/Kg/day): (Figure 1a)
 - <0,6: 9 p (8,3%)
 - 0,6-0,79: 11 p (18,3%)
 - 0,8-0,99: 14 p (23,3%)
 - *1-1,19: 17 p (28,3%)
 - *1,2: 13 p (21,6%)
- Albumin and dp nPCR profiles (Figure 1b)**
- Catabolic (Albumin < 38 g/L)
 - dp nPCR \geq 1 g/Kg/day: 12 p (20%)
 - Low intake (Albumin < 38 g/L)
 - dp nPCR < 1 g/Kg/day: 21 p (35%)
 - High intake (Albumin \geq 38 g/L)
 - dp nPCR \geq 1 g/Kg/day: 19 p (31,6%)
 - Anabolic (Albumin \geq 38 g/L)
 - dp nPCR < 1 g/Kg/day: 8 p (13,3%)
- Dependent variables:**
- Albumin
 - dp nPCR
- Categorical factors:**
- IS2 mean / $<$ mean
 - β_2M 2 mean / $<$ mean

Urea

Albumin + 83-97% Indoxyl sulfate



MHC-I β_2 -microglobulin



	X±SE (mg/L)	Range (mg/L)	Hemodiafiltration p	Standard HD p	Normal values	Mortality risk augmented
β_2M	35,6±1,9	11,5-72,1	32,8±1,9 mg/L	38,2±3,1 mg/L	<3,5mg/L	>25mg/L
IS	18,91±1,63	0,28-55,12	22,4±2,7 mg/L	16,04±1,6 mg/L	<1,2mg/L	>4mg/L

RESULTS 1:

β_2M and IS means in the whole population and in the hemodiafiltration and standard hemodialysis patients

	Total	Hemodiafiltration p	Standard HD p
Urea Reduction Rate	78,6±1,1 %	82,04±1,1 %	75,2±1,6 %
β_2 microglobulin Reduction Rate		79,8±1,1 %	
Indoxyl sulfate Reduction Rate	47,1±2,1 %	49,07±2,8 %	45,2±3,1 %

RESULTS 2:

Urea, β_2M and IS reduction rates

	Mean IS (CI 95%)	p	Mean β_2M (CI 95%)	p
CRP \geq 1 mg/dl (n=22)	17,5 (11,7-23,3)	NS	43,9 (37,3-50,4)	0.0006
CRP < 1 mg/dl (n=38)	19,7 (15,6-23,8)		30,8 (26,6-34,9)	
Albumin \geq 38 g/L (n=25)	22,2 (16,5-27,9)	NS	29,4 (24,7-34,2)	0.002
Albumin < 38 g/L (n=35)	16,5 (12,6-20,4)		40,9 (35,6-46,1)	
dp nPCR \geq 1 g/Kg/day (n=31)	22,8 (18-27,6)	0.01	36,3 (35,5-41,1)	NS
dp nPCR < 1 g/Kg/day (n=29)	14,4 (10,6-18,8)		35,9 (29,5-42,4)	

RESULTS 3: Student-t Test

Uremic toxins means as dependent variables vs CRP, albumin and protein catabolic rate as categorical factors:

	Mean Albumin (CI 95%)	p	Mean dp nPCR (CI 95%)	p
IS 18,9 \geq mg/L (n=26)	38,1 (36,5-39,7)	NS	1,08 (0,98-1,18)	0,03
IS 18,9 < mg/L (n=34)	37,4 (35,8-39)		0,93 (0,83-1,03)	
β_2M 35,6 \geq mg/L (n=25)	35,7(33,8-37,7)	0,001	0,99 (0,85-1,13)	NS
β_2M 35,6 < mg/L (n=35)	39,1 (38-40,3)		1 (0,92-1,08)	


RESULTS 4: Student-t Test

Albumin and protein catabolic rate means as dependent variables vs uremic toxins as categorical factors:

RESULTS 7: MULTIPLE REGRESSION



- Indoxyl sulfate: Adjusted R² = 0,24
- Mean arterial pressure change p=0,01
- P = 0,01
- BUN p=0,03
- TAC urea p=0,04
- Indoxyl sulfate reduction rate: Adjusted R² = 0,34
- Mean arterial pressure change p=0,007
- β_2 microglobulin: Adjusted R² = 0,26
- Residual diuresis p=0,001
- Albumin p=0,01
- β_2 microglobulin reduction rate: Adjusted R² = 0,65
- Infusion volume p=0,0009
- G2p urea p=0,002
- TAC urea p=0,01

RESULTS 8: MEAN ARTERIAL PRESSURE CHANGE



RESULTS 6: SIGNIFICANT BIVARIATE CORRELATIONS

- Indoxyl sulfate:
 - P: r / r²=0,11 / p=0,007
 - BUN: r / r²=0,11 / p=0,009
 - Albumin: r / r²=0,10 / p=0,01
 - TAC urea: r / r²=0,09 / p=0,01
 - PCRn_2P: r / r²=0,08 / p=0,02
 - MAP change: r / r²=0,08 / p=0,02
- Indoxyl sulfate reduction rate:
 - G2p urea: r / r²=0,17 / p=0,0008
 - Eq Kt/V: r / r²=0,15 / p=0,002
 - Height: r / r²=0,11 / p=0,007
 - MAP change: r / r²=0,11 / p=0,008
 - TAC urea: r / r²=0,11 / p=0,009
 - BSA: r / r²=0,08 / p=0,02
 - HCO₃: r / r²=0,19 / p=0,01
 - BUN: r / r²=0,07 / p=0,04
- β_2 microglobulin:
 - Residual diuresis: r / r²=0,17 / p=0,001
 - Albumin: r / r²=0,11 / p=0,007
 - Log CRP: r / r²=0,07 / p=0,03
- β_2 microglobulin reduction rate:
 - G2p urea: r / r²=0,32 / p=0,001
 - Log CRP: r / r²=0,30 / p=0,001
 - Eq Kt/V: r / r²=0,27 / p=0,003
 - Infusion volume: r / r²=0,21 / p=0,01
 - BSA: r / r²=0,17 / p=0,02
 - TAC urea: r / r²=0,16 / p=0,02



RESULTS 5: ANOVA

IS and β_2M as dependent variables vs dp nPCR categorized by levels (Figure 1a) and vs albumin/dp nPCR profiles (Figure 1b)

BIBLIOGRAPHY

- Meyer T et al. Uremic solutes from colon microbes. *Kidney International* 82: 949-954, 2012 / Koyen G et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. *Kidney Int* 60: 333-340, 2001 / Visconti L et al. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. *Biofarm Drug Dispos* 34: 165-175, 2013 / Meijers B et al. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. *Nephrol Dial Transplant* 26: 759-761, 2011 / Tsumura Z et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF- κ B activation. *Am J Nephrol* 31: 435-441, 2010 / Yu M et al. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. *Clin J Am Soc Nephrol* 6: 30-39, 2011 / Sun Ch et al. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. *Nephrol Dial Transplant* 0: 1-9, 2012 / Sun Ch et al. Suppression of IkappaB expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. *Kidney Int* 81: 640-650, 2012 / Barreto F et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. *Clin J Am Soc Nephrol* 4: 1551-1558, 2009 / Meijers B et al. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. *Clin J Am Soc Nephrol* 4: 1932-1938, 2009 / Canaud B et al. β_2 -microglobulin, a uremic toxin with a double meaning. *Kidney Int* 69: 1291-1299, 2006 / Schwab S et al. β_2 -microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis. *Kidney Int* 52: 1077-1083, 1997 / Gejyo F et al. β_2 -microglobulin: a new form of amyloid protein associated with chronic hemodialysis. *Kidney Int* 30: 385-390, 1986 / Kazama Y et al. Reduction of circulating β_2 -microglobulin level for the treatment of dialysis-related amyloidosis. *Nephrol Dial Transplant* 16 (Suppl 4): 31-35, 2001 / Niwa T et al. Amyloid β_2 -microglobulin is modified with N epsilon-(carboxymethyl) lysine in dialysis-related amyloidosis. *Kidney Int* 50: 1303-1309, 1996 / Miyata T et al. Involvement of β_2 -microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemoattractant and macrophage secretion of tumor necrosis factor- α and interleukin-1. *J Clin Invest* 93: 522-528, 1994 / Miyata T et al. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). *Kidney Int Suppl* 78: S25-S31, 2001 / Okano S et al. Serum β_2 -microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. *Nephrol Dial Transplant* 24: 571-577, 2009 / Vanholder R et al. Do we need new indicators of dialysis adequacy based on middle molecule removal? *Nat Clin Pract Nephrol* 4: 174-175, 2008 / Cheung A et al. Serum β_2 -microglobulin levels predict mortality in dialysis patients: results of the HEMO study. *J Am Soc Nephrol* 17: 546-555, 2006 / Cheung A et al. Association between serum β_2 -microglobulin level and infectious mortality in hemodialysis patients. *Clin J Am Soc Nephrol* 2008; 3: 69-77.

CONCLUSIONS

- Indoxyl sulfate levels had direct correlation with normalized protein catabolic rate, phosphorus, albuminemia, BUN and TAC urea.
- β_2 microglobulin had inverse correlation to albumin and direct correlation with C-reactive protein.
- Residual diuresis was the strongest predictive variable for β_2 microglobulin serum concentration in the multiple regression analysis.
- Indoxyl sulfate highest and lowest levels in high and low protein intake patients.
- Catabolic patients had the highest and anabolic patients the lowest β_2 microglobulin levels.
- Mean arterial pressure change linked to indoxyl sulfate and indoxyl sulfate reduction rate.
- Indoxyl sulfate determined by protein intake.
- β_2 microglobulin determined by malnutrition-inflammation.

